{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:59:38Z","timestamp":1786993178398,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.josat.2024.209348","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:55:30Z","timestamp":1710510930000},"page":"209348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products"],"prefix":"10.1016","volume":"162","author":[{"given":"Mark R.C.","family":"Daglish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Hayllar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209348_bb0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.josat.2024.209348_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103492","article-title":"Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence","volume":"100","author":"Farrell","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"8","key":"10.1016\/j.josat.2024.209348_bb0015","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction"},{"issue":"10173","key":"10.1016\/j.josat.2024.209348_bb0020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.josat.2024.209348_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s40814-023-01348-5","article-title":"Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: A pilot study","volume":"9","author":"Hard","year":"2023","journal-title":"Pilot and Feasibility Studies"},{"key":"10.1016\/j.josat.2024.209348_bb0030","doi-asserted-by":"crossref","unstructured":"Iacono, A., Wang, T., Tadrous, M., Campbell, T., Kolla, G., Leece, P., Sproule, B., Kleinman, R. A., Besharah, J., Munro, C., Doolittle, M., & Gomes, T. (2024). Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada. Drug and Alcohol Dependence, 254, article 111032. doi:https:\/\/doi.org\/10.1016\/j.drugal-cdep.2023.111032.","DOI":"10.1016\/j.drugalcdep.2023.111032"},{"issue":"8","key":"10.1016\/j.josat.2024.209348_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v038.i08","article-title":"Multi-state models for panel data: The msm package for R","volume":"38","author":"Jackson","year":"2011","journal-title":"Journal of Statistical Software"},{"issue":"7","key":"10.1016\/j.josat.2024.209348_bb0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jcph.665","article-title":"Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder","volume":"56","author":"Laffont","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1016\/j.josat.2024.209348_bb0045","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.josat.2024.209348_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2024.209348_bb0055","series-title":"R: A Language and Environment for Statistical Computing (Version 4.3.2)","author":"R Core Team","year":"2023"},{"key":"10.1016\/j.josat.2024.209348_bb0060","series-title":"RStudio: Integrated development environment for R (version 2023.03.0-386)","author":"RStudio Team","year":"2023"},{"key":"10.1016\/j.josat.2024.209348_bb0065","author":"Therneau"},{"key":"10.1016\/j.josat.2024.209348_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103788","article-title":"Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot","volume":"107","author":"Treloar","year":"2022","journal-title":"International Journal of Drug Policy"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924000602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:09:17Z","timestamp":1714349357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":14,"alternative-id":["S2949875924000602"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209348","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Australian retrospective observational cohort comparison of the use of long-acting injectable buprenorphine products","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209348"}}